Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | CCR3 | P51677 | 5/20 | 0.74 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.73 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.73 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.73 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035825 | 0.90 | KMT2A (0.81) | MEN1KMT2ACCR3MCHR1SIGMAR1 | |
| SCHEMBL4034737 | 0.87 | SIGMAR1 (0.81) | MEN1KMT2ACCR3SIGMAR1 | |
| SCHEMBL18844433 | 0.85 | CCR3 (1.00) | CCR3MCHR1SIGMAR1SLC6A12TMEM97 | |
| SCHEMBL1425074 | 0.84 | SIGMAR1 (1.00) | MEN1KMT2ACCR3MCHR1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9785680 | 0.83 | SIGMAR1 (0.97) | MEN1KMT2ACCR3MCHR1SIGMAR1 | |
| SCHEMBL17946338 | 0.82 | KMT2A (0.80) | MEN1KMT2AMCHR1SIGMAR1SLC6A12 | |
| SCHEMBL4031765 | 0.82 | KMT2A (0.72) | MEN1KMT2AMCHR1SIGMAR1DRD2 | |
| SCHEMBL2213082 | 0.82 | SIGMAR1 (0.76) | MEN1KMT2ACCR3MCHR1SIGMAR1 | |
| SCHEMBL17950985 | 0.82 | POLB (0.63) | MEN1KMT2AMCHR1SIGMAR1 | |
| SCHEMBL6312739 | 0.82 | SIGMAR1 (0.76) | MEN1KMT2AMCHR1SIGMAR1SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | MEN1 4130/4885KMT2A 2580/4885CCR3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.